Jessica Hope Roark

Array ( [id] => 17058949 [patent_doc_number] => 11103531 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Compositions and methods for immunotherapy [patent_app_type] => utility [patent_app_number] => 16/148687 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 45 [patent_no_of_words] => 25420 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072383 [patent_doc_number] => 20190085079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING [patent_app_type] => utility [patent_app_number] => 16/145790 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16145790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16665128 [patent_doc_number] => 10934361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Antibody therapeutics that bind CD123 [patent_app_type] => utility [patent_app_number] => 16/135886 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18740 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156603 [patent_doc_number] => 20200216534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED NFKB SIGNALING [patent_app_type] => utility [patent_app_number] => 16/632091 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339309 [patent_doc_number] => 12049487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Universal chimeric antigen receptor T-cell preparation technique [patent_app_type] => utility [patent_app_number] => 16/645290 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 12 [patent_no_of_words] => 12441 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043539 [patent_doc_number] => 20190077876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/105651 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16105651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778059 [patent_doc_number] => 20190002568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => BISPECIFIC FC MOLECULES [patent_app_type] => utility [patent_app_number] => 16/032342 [patent_app_country] => US [patent_app_date] => 2018-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16032342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13824039 [patent_doc_number] => 20190015504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/026815 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536697 [patent_doc_number] => 20180319892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT [patent_app_type] => utility [patent_app_number] => 16/024376 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964202 [patent_doc_number] => 11897953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Compositions and methods targeting complement component 3 for inhibiting tumor growth [patent_app_type] => utility [patent_app_number] => 16/622636 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 59 [patent_no_of_words] => 59960 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13479143 [patent_doc_number] => 20180291114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => RECOMBINANT BI-SPECIFIC POLYPEPTIDE FOR COORDINATELY ACTIVATING TUMOR-REACTIVE T-CELLS AND NEUTRALIZING IMMUNE SUPPRESSION [patent_app_type] => utility [patent_app_number] => 16/007035 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17859815 [patent_doc_number] => 11440961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Anti TRBC1 antigen binding domains [patent_app_type] => utility [patent_app_number] => 16/620370 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 10963 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14214033 [patent_doc_number] => 20190119401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS [patent_app_type] => utility [patent_app_number] => 15/994393 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15994393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043501 [patent_doc_number] => 20190077857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => METHODS RELATED TO ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 15/975548 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15975548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551883 [patent_doc_number] => 20180327489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES [patent_app_type] => utility [patent_app_number] => 15/973735 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15973735 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839495 [patent_doc_number] => 20210147507 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION [patent_app_type] => utility [patent_app_number] => 16/611772 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13522121 [patent_doc_number] => 20180312603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS [patent_app_type] => utility [patent_app_number] => 15/971647 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15971647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386527 [patent_doc_number] => 20180244805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => CYTOTOXICITY-INDUCING THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 15/963221 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15963221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274642 [patent_doc_number] => 11613573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Chimeric antibody/T-cell receptor constructs and uses thereof [patent_app_type] => utility [patent_app_number] => 16/608336 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 87413 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16726519 [patent_doc_number] => 20210093666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND SECONDARY EFFECTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/608362 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608362 [rel_patent_id] =>[rel_patent_doc_number] =>)